桂枝茯苓胶囊联合米非司酮对子宫肌瘤患者的临床疗效及对血清VEGF、MMP-9、CA125、E2水平的影响

摘要 目的：研究桂枝茯苓胶囊联合米非司酮对子宫肌瘤患者的临床疗效及对血清血管内皮生长因子(VEGF)、基质金属蛋白酶-9(MMP-9)、糖类抗原(CA125)、性激素卵泡雌激素(FSH)、黄体生成素(LH)、雌二醇(E2)]水平的影响。方法：选取2014年5月至2015年4月我院收治的子宫肌瘤患者76例，根据患者入院顺序分为观察组和对照组，38例每组。对照组使用米非司酮完成治疗，观察组在对照组治疗基础上联合桂枝茯苓胶囊完成治疗。比较两组患者临床疗效，治疗前后血清VEGF、MMP-9、CA125、E2水平的变化。结果：治疗后，观察组临床总有效率显著高于对照组89.47%(34/38)比60.53%(23/38)](P<0.05)；两组患者血清FSH、LH、E2、VEGF、MMP-9、CA125水平均较治疗前显著降低(P<0.05)，和对照组相比，观察组以上指标显著降低(P<0.05)。观察组和对照组不良反应的发生率比较差异无统计学意义(P>0.05)。结论：桂枝茯苓胶囊联合米非司酮治疗子宫肌瘤可显著提高其临床疗效，且安全性高，可能与其能有效降低子宫肌瘤患者血清VEGF、MMP-9、CA125、FSH、LH、E2水平有关。

Clinical Efficacy of Guizhi Fuling Capsule Combined with Mifepristone in the Treatment of Patients with Uterine Leiomyoma and Effects on the Serum VEGF, MMP-9, CA125 and E2 Levels

ABSTRACT Objective: To study the clinical efficacy of guizhi fuling capsule combined with mifepristone in the treatment of patients with uterine leiomyoma and its effects on the levels of serum vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), carbohydrate antigen (CA125 ), sex hormones follicle estrogen (FSH), luteinizing hormone (LH), estradiol (E2)]. Methods: 76 cases of patients with uterine fibroids treated in our hospital from May 2014 to April 2015 were selected and divided into the observation group and the control group according to the order of admission. The control group was treated with mifepristone. The observation group was treated with Guizhi Fuling Capsule on the basis of control group. The clinical efficacy, changes of the levels of serum VEGF, MMP-9, CA125 and E2 before and after treatment were compared between two groups. Results: After treatment, the total effective rate of observation group was significantly higher than that of the control group 89.47%(34/38) vs 60.53%(23/38)](P <0.05). The levels of serum FSH, LH, E2, VEGF, MMP-9 and CA125 in both groups were significantly lower than those before treatment (P <0.05). Compared with the control group, the above indexes in the observation group were significantly decreased (P <0.05). There was no significant difference in the incidence of adverse reactions between the observation group and the control group (P> 0.05). Conclusion: Guizhi Fuling Capsule combined with mifepristone could significantly improve the clinical efficacy in the treatment of uterine fibroids with high safety, which might be related to effective reduce of the levels of serum VEGF, MMP-9, CA125, FSH, LH and E2.